Ariba & Mac provides pharmaceutical and healthcare due diligence for investors, VCs, banks and boards evaluating assets, companies, facilities, technology platforms or development projects. Reviews combine scientific, CMC, clinical, regulatory, quality, operational, commercial and capital perspectives according to the investment question.
Life-sciences and healthcare investments can look attractive at headline level while material risk sits deeper in the data: incomplete technical validation, regulatory dependencies, weak quality systems, unrealistic scale-up assumptions, hidden capital requirements, single-vendor dependence or commercial forecasts that are not supported by the execution plan. Our diligence process is designed to surface those dependencies before capital is committed.
For Saudi opportunities, the review can incorporate the intended local regulatory pathway, facility or manufacturing model, localization assumptions, private-sector healthcare context and the practical steps required to operate in the Kingdom, while separating verified facts from management assumptions that still need evidence.
Pharma & Healthcare Investor Due Diligence Deliverables
The scope is built around the investment decision, with findings organized by materiality so the investor can distinguish manageable execution work from issues that could alter valuation, timing or investment thesis.
- Asset, product, pipeline or facility review combining technical evidence with the stated commercial and development strategy.
- Risk and gap analysis across CMC, clinical, regulatory, quality and operational systems, including dependencies between workstreams.
- Technology and IP-position review, including platform maturity and freedom-to-operate considerations that require specialist legal or patent input.
- Capital and operating assumptions, milestone requirements and scenario inputs to test whether the execution plan is consistent with the stated funding need.
- Vendor, CDMO, CRO and critical-supplier dependency review, including capability, concentration and implementation risk.
- Market, competition, access and pricing-assumption review to test the commercial narrative against the intended geography and route to market.
- Post-investment monitoring framework with milestones, KPIs, risk owners and reporting cadence for critical technical and regulatory value drivers, with optional transition into turnkey execution support.
Technical & Regulatory Risk
Assess whether the scientific evidence, CMC maturity, clinical plan, quality system and regulatory pathway support the development claims and timeline presented to the investor.
Commercial & Capital Review
Challenge key market, pricing, capacity, CapEx, OpEx and timeline assumptions and identify where the financial model depends on technical milestones that are not yet de-risked.
Execution & Governance
Evaluate whether the team, vendors, decision rights, milestones and reporting model are strong enough to deliver the plan after the transaction or funding event.
Healthcare & Life Sciences Due Diligence Process for Investors
We begin with the investment thesis and the decisions the client must make, then tailor the data request and specialist review to the risks most capable of changing value, timing or execution feasibility.
- Separate verified evidence, management assumptions and unresolved questions so the investor can see which conclusions are supported and which still require validation.
- Report findings by materiality and actionability, with clear implications for valuation, conditions precedent, additional diligence, post-close priorities or project governance.
1. Define Investment Questions & Data Requirements
Clarify the transaction or funding decision, review the available data room, identify missing evidence and assign specialist review areas based on the asset and investment thesis.
2. Validate Assumptions & Prioritize Risks
Cross-check technical, regulatory, quality, commercial and capital assumptions; identify dependencies and red flags; and produce a decision-oriented findings and action framework.
Specialist Pharma & Healthcare Due Diligence Before Capital Is Committed
Pharma and healthcare value is often milestone-dependent. A scientific, regulatory or quality issue can directly change the commercial model, capital requirement or time to revenue, so these areas should not be reviewed in isolation.
Multidisciplinary Review
Scientific, CMC, clinical, quality, regulatory, operational and commercial evidence can be assessed together so one team’s assumption is checked against the dependencies in another workstream.
Decision-Oriented Findings
Reports focus on material risks, evidence gaps, implications and recommended next actions rather than producing a long checklist with no investment prioritization.
Post-Investment Continuity
Critical diligence findings can be converted into milestones, KPIs and governance actions so the investor can monitor whether the identified risks are actually being reduced after funding.
Independent Technical Due Diligence Requires Clear Scope & Boundaries
We distinguish evidence from assumptions and identify where legal, tax, accounting, patent or other licensed professional opinions are required outside the technical-consulting scope. The purpose is to improve the investor’s decision quality, not to manufacture certainty where the underlying evidence is incomplete.
Authoritative Regulatory, Government & Academic Resources
For current official requirements, standards and sector guidance, consult the relevant authority directly. These independent external resources are provided for reference and do not imply affiliation or replace project-specific regulatory, legal or clinical advice.
- Saudi Ministry of Health – Private Sector Participation — Official policy context for investment and private-sector participation in Saudi healthcare.
- Saudi Ministry of Health – Healthcare Financing Initiative — Official information on financing initiatives supporting healthcare investment in the Kingdom.
- SFDA Laws and Regulations — Official Saudi regulatory repository for product and establishment requirements relevant to technical diligence.
FAQs About Pharma & Healthcare Due Diligence in Saudi Arabia
The answer depends on the asset, but common areas include scientific evidence, CMC/manufacturing maturity, clinical plan, regulatory pathway, quality systems, IP/technology, vendors, capital requirements, market assumptions, team capability and execution governance.
Yes. The review can include the intended Saudi regulatory and operating model, local facility or manufacturing requirements, partner dependencies and the assumptions behind market entry, localization or healthcare-service delivery.
We can support technical and commercial inputs, capital assumptions, milestone risk and scenario analysis that inform valuation. Formal valuation, legal and tax opinions should be provided by the appropriately qualified advisers where required.
We can review the technology position, development claims and obvious dependency questions and coordinate specialist input. Formal freedom-to-operate or patent opinions should be completed by qualified IP counsel.
Yes. We review whether critical vendors are qualified, replaceable, appropriately governed and capable of supporting the stated timeline, quality and scale assumptions.
Yes. Material findings can be converted into milestone conditions, risk owners, KPIs and reporting cadence so the investor can track technical, regulatory and operational de-risking after the investment.